Detection of Atherosclerotic Inflammation by <sup>68</sup>Ga-DOTATATE PET Compared to [<sup>18</sup>F]FDG PET Imaging.
Level II
Where this comes from
- Record sourced from PubMed, PMID 28385306.
- Also identified by DOI 10.1016/j.jacc.2017.01.060 and PMC identifier 5381358.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Inflammation drives atherosclerotic plaque rupture. Although inflammation can be measured using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([<sup>18</sup>F]FDG PET), [<sup>18</sup>F]FDG lacks cell specificity, and coronary imaging is unreliable because of myocardial spillover. This study tested the efficacy of gallium-68-labeled DOTATATE (<sup>68</sup>Ga-DOTATATE), a somatostatin receptor subtype-2 (SST<sub>2</sub>)-binding PET tracer, for imaging atherosclerotic inflammation. We confirmed <sup>68</sup>Ga-DOTATATE binding in macrophages and excised carotid plaques. <sup>68</sup>Ga-DOTATATE PET imaging was compared to [<sup>18</sup>F]FDG PET imaging in 42 patients with atherosclerosis. Target SSTR2 gene expression occurred exclusively in "proinflammatory" M1 macrophages, specific <sup>68</sup>Ga-DOTATATE ligand binding to SST<sub>2</sub> receptors occurred in CD68-positive macrophage-rich carotid plaque regions, and carotid SSTR2 mRNA was highly correlated with in vivo <sup>68</sup>Ga-DOTATATE PET signals (r = 0.89; 95% confidence interval [CI]: 0.28 to 0.99; p = 0.02). <sup>68</sup>Ga-DOTATATE mean of maximum tissue-to-blood ratios (mTBR<sub>max</sub>) correctly identified culprit versus nonculprit arteries in patients with acute coronary syndrome (median difference: 0.69; interquartile range [IQR]: 0.22 to 1.15; p = 0.008) and transient ischemic attack/stroke (median difference: 0.13; IQR: 0.07 to 0.32; p = 0.003). <sup>68</sup>Ga-DOTATATE mTBR<sub>max</sub> predicted high-risk coronary computed tomography features (receiver operating characteristics area under the curve [ROC AUC]: 0.86; 95% CI: 0.80 to 0.92; p < 0.0001), and correlated with Framingham risk score (r = 0.53; 95% CI: 0.32 to 0.69; p <0.0001) and [<sup>18</sup>F]FDG uptake (r = 0.73; 95% CI: 0.64 to 0.81; p < 0.0001). [<sup>18</sup>F]FDG mTBR<sub>max</sub> differentiated culprit from nonculprit carotid lesions (median difference: 0.12; IQR: 0.0 to 0.23; p = 0.008) and high-risk from lower-risk coronary arteries (ROC AUC: 0.76; 95% CI: 0.62 to 0.91; p = 0.002); however, myocardial [<sup>18</sup>F]FDG spillover rendered coronary [<sup>18</sup>F]FDG scans uninterpretable in 27 patients (64%). Coronary <sup>68</sup>Ga-DOTATATE PET scans were readable in all patients. We validated <sup>68</sup>Ga-DOTATATE PET as a novel marker of atherosclerotic inflammation and confirmed that <sup>68</sup>Ga-DOTATATE offers superior coronary imaging, excellent macrophage specificity, and better power to discriminate high-risk versus low-risk coronary lesions than [<sup>18</sup>F]FDG. (Vascular Inflammation Imaging Using Somatostatin Receptor Positron Emission Tomography [VISION]; NCT02021188).
Medical subject headings
- Atherosclerosis
- Fluorodeoxyglucose F18
- Inflammation
- Organometallic Compounds
- Positron Emission Tomography Computed Tomography